Skip to main content

Table 1 Patient demographics, clinical and laboratory parameters of AS patients on different stages of hip involvement

From: Assessment of hip involvement in patients with ankylosing spondylitis: reliability and validity of the Hip Inflammation MRI Scoring System

 

Total AS patients

Group A (n = 21)

Group B (n = 42)

Group C (n = 25)

P value

Adjusted P value

A-B

A-C

B-C

Male gender, n (%)

72 (81.8%)

20 (95.2%)

33 (78.6%)

19 (76.0%)

0.175

   

Age at outpatient visit (years)

30.00 (25.25, 34.75)

32.00 (30.00, 39.00)

30.00 (25.50–34.25)

28.50 (25.00–35.00)

0.147

   

Age at onset (years)

23.00 (19.00, 26.00)

25.00 (23.00, 28.00)

22.00 (18.00, 27.25)

21.50 (17.00, 24.00)

0.005*

0.093

0.004*

0.390

Disease duration (years)

6.50 (2.00, 10.50)

6.00 (2.00, 11.00)

6.00 (2.00, 9.00)

7.00 (2.00, 11.00)

0.812

   

Diagnosis delay (years)

2.00 (0.25, 8.00)

1.00 (0.00, 6.00)

2.00 (0.00, 8.00)

2.00 (1.00, 10.50)

0.233

   

Family history, n (%)

27 (30.7%)

6 (28.6%)

9 (21.4%)

12 (48.0%)

0.081

   

EAMs, n (%)

14 (15.9%)

1 (4.8%)

7 (16.7%)

6 (24.0%)

0.213

   

Uveitis, n (%)

3 (3.4%)

0 (0.0%)

0 (0.0%)

3 (12.0%)

0.033*

\

0.239

0.048*

IBD, n (%)

7 (8.0%)

1 (4.8%)

5 (11.9%)

1 (4.0%)

0.595

   

Psoriasis, n (%)

4 (4.4%)

0 (0.0%)

2 (4.8%)

2 (8.0%)

0.570

   

Use of NSAIDs, n (%)

82 (93.2%)

19 (90.5%)

39 (92.9%)

24 (96.0%)

0.327

   

Use of DMARDs, n (%)

36 (40.9%)

8 (38.1%)

17 (40.5%)

11 (44.0%)

0.922

   

BMI

25.95 (22.86, 29.09)

27.12 (23.12, 29.93)

25.81 (22.86, 29.36)

25.95 (19.59, 28.98)

0.752

   

HLA-B27 positivity, n (%)

80 (90.9%)

21 (100.0%)

38 (90.5%)

21 (84.0%)

0.165

   

ESR (mm)

25.50 (13.00, 38.00)

13.00 (10.00, 24.50)

25.00 (13.00, 39.25)

29.00 (25.00, 41.25)

 < 0.001*

0.016*

 < 0.001*

0.296

CRP (mg/L)

14.80 (9.30, 27.80)

13.20 (6.60, 15.56)

14.30 (5.28, 27.80)

24.20 (12.70, 53.80)

0.003*

0.610

0.003*

0.032*

hsCRP(mg/L)

13.54 (4.60, 28.17)

7.70 (4.93, 20.44)

12.20 (3.42, 29.49)

25.96 (8.83, 34.24)

0.031*

0.869

0.031*

0.179

ALB (g/L)

45.50 (43.00, 47.45)

44.90 (41.30, 46.80)

46.30 (43.95, 47.70)

43.90 (43.00, 46.65)

0.134

   

HGB(g/L)

142.00 (133.00, 150.00)

145.00 (141.00–159.00)

143.00 (131.50–152.00)

141.00 (130.00–149.00)

0.123

   

BASDAI

3.20 (1.80, 5.35)

2.00 (1.40, 3.00)

3.40 (1.65, 5.25)

4.60 (3.20, 5.80)

 < 0.001*

0.070

 < 0.001*

0.023*

BASFI

1.60 (0.73, 2.60)

0.70 (0.60, 1.30)

1.80 (0.80, 2.90)

2.00 (1.60, 2.83)

 < 0.001*

0.001*

 < 0.001*

0.214

ASQOL

6.00 (2.00, 8.00)

2.00 (2.00, 3.00)

6.00 (2.75, 8.00)

7.00 (6.00, 11.75)

0.001*

0.011*

0.001*

0.541

ASDAS-ESR

2.35 (1.83, 3.10)

1.79 (1.05–1.96)

2.44 (1.90–3.48)

2.93 (2.35–3.55)

 < 0.001*

 < 0.001*

 < 0.001*

0.443

ASDAS-CRP

2.45 (1.61, 3.23)

1.54 (1.43, 1.98)

2.52 (1.79, 3.46)

2.63 (2.37, 3.42)

 < 0.001*

 < 0.001*

 < 0.001*

0.538

SF-12PCS

42.20 (27.70, 52.20)

50.10 (39.00, 55.40)

42.20 (28.38, 50.40)

32.10 (22.80, 51.83)

0.020*

0.092

0.020*

1.000

SF-12MCS

42.75 (27.50, 53.50)

52.20 (40.00, 54.75)

42.35 (29.45, 53.50)

31.90 (25.40, 51.75)

0.038*

0.279

0.032*

0.675

HHS

86.00 (67.00, 94.75)

95.00 (93.00, 96.00)

77.00 (54.00, 89.75)

69.00 (51.50, 87.00)

 < 0.001*

 < 0.001*

 < 0.001*

0.875

BARSI

2.00 (1.00, 3.00)

1.00 (1.00, 1.00)

2.00 (1.00, 2.00)

3.00 (3.00, 4.00)

 < 0.001*

0.002*

 < 0.001*

 < 0.001*

HIMRISS

29.63 (15.25, 43.00)

14.50 (11.38, 22.25)

29.38 (17.00, 40.94)

38 (31.13, 64.38)

 < 0.001*

0.009*

 < 0.001*

0.103

  1. *P < 0.05, AS ankylosing spondylitis, EAMs extra-articular manifestations, IBD inflammatory bowel disease, NSAIDs nonsteroidal anti-inflammatory drugs, DMARDs disease modifying anti-rheumatic drugs, BMI bone mass density, HLA-B27 human leucocyte antigen-B 27, ESR erythrocyte sedimentation rate, CRP C reactive protein, hsCRP high sensitive C reactive protein, ALB albumin, HGB hemoglobin, BASDAI Bath ankylosing spondylitis disease activity index, BASFI Bath ankylosing spondylitis functional index, ASQOL ankylosing spondylitis quality of life, ASDAS Ankylosing Spondylitis Disease Activity Score, SF-12 PCS short form-12 physical component summary, SF-12 MCS short form-12 mental component summary, HHS Harris hip score, BASRI-Hip the bath ankylosing spondylitis radiology hip index
  2. Group A represents the hips with no hip involvement (HHS ≥ 80 and BASRI ≤ 1), group B represents the hips with mild hip involvement (BASRI = 2 or BASRI ≤ 1 and HHS ≤ 79) and Group C represents the hips with advanced hip involvement (BASRI ≥ 3)
  3. The value of continuous variables was presented as median and quartile (25–75%) and the categorical variables were based on presented as number plus percentage
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us